Small orphan drug firms caught by Germany's AMNOG assessments
This article was originally published in SRA
Executive Summary
Small companies with orphan drug products whose turnover is less than €50 million ($68 million) are not excluded from cost-effectiveness assessments introduced this year under Germany's healthcare reform act, warned Alexander Natz, Brussels representative for the BPI, the German association for mid-sized pharma companies1.